Sanofi India Q1 Review - Cost Control Boosts Margin: ICICI Securities
A person tests the flow of a Sanofi Lantus brand SoloStar insulin pen in an arranged photograph (Photographer Alex Flynn/Bloomberg)

Sanofi India Q1 Review - Cost Control Boosts Margin: ICICI Securities

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Securities Report

Sanofi India Ltd.’s Q1 CY21 performance was supported by controlled costs.

Revenue declined 7.6% year-on-year to Rs 7.3 billion but sequentially it remained stable.

Ebitda margin improved 360 basis points YoY and 290 bps quarter-on-quarter with lower expenses to 26.1%.

Adjusted profit after tax grew 24.3% to Rs 1.5 billion.

As per All India Organisation of Chemists and Druggists data, company reported a YoY growth of 2.9% for the quarter.

In the past few years, the company’s growth and profitability was fuelled by the power brands.

Click on the attachment to read the full report:

ICICI Securities Sanofi Q1CY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.